menu

Loading...

VNRX Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

0.216

Open

0.214

VWAP

0.20

Vol

2.15M

Mkt Cap

27.48M

Low

0.190

Amount

436.08K

EV/EBITDA(TTM)

--

Total Shares

135.57M

EV

38.94M

EV/OCF(TTM)

--

P/S(TTM)

14.51

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Show More

Events Timeline

(ET)

2026-02-09

17:30:00

VolitionRx Receives NYSE Warning, Must Submit Compliance Plan

2026-02-09

17:20:00

VolitionRx Files to Sell 17.97M Shares of Common Stock

2026-01-20 (ET)

2026-01-20

08:30:00

VolitionRx Appoints New Lab Providers to Expand Nu.Q Vet Cancer Test

2026-01-08 (ET)

2026-01-08

08:50:00

VolitionRx Announces Results of Cat Lymphoma Detection Study

2025-12-11 (ET)

2025-12-11

09:20:00

VolitionRx Releases Manuscript Showcasing New Cancer Biomarkers for Liquid Biopsy

2025-11-13 (ET)

2025-11-13

16:16:23

VolitionRx Announces Q3 Revenue of $600,000, Below Consensus Estimate of $715,590

2025-10-10 (ET)

2025-10-10

08:34:46

VolitionRx reveals pricing for $6M common stock and warrant offering

News

seekingalpha

02-09seekingalpha

VolitionRx Receives NYSE Compliance Notice

Globenewswire

01-21Globenewswire

Venus Concept Inc. Announces Voluntary Delisting from NASDAQ to Cut Compliance Costs

PRnewswire

01-20PRnewswire

VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia

Newsfilter

01-20Newsfilter

VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia

Newsfilter

01-16Newsfilter

VolitionRx Sponsors VMX 2026, Showcases Nu.Q® Vet Cancer Test

PRnewswire

01-16PRnewswire

VolitionRx Sponsors VMX 2026, Showcases Nu.Q® Vet Cancer Test

3 Analyst Rating

Wall Street analysts forecast VNRX stock price to rise

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

1.50

Averages

2.25

High

3.00

Current: 0.000

Low

1.50

Averages

2.25

High

3.00

Maxim

Buy

to

Hold

downgrade

AI Analysis

2025-12-03

Reason

Maxim

Price Target

AI Analysis

2025-12-03

downgrade

Buy

to

Hold

Reason

Maxim downgraded VolitionRx to Hold from Buy.

H.C. Wainwright

H.C. Wainwright

Buy

downgrade

2025-11-17

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

2025-11-17

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on VolitionRx (VNRX) to $1.50 from $2.50 and keeps a Buy rating on the shares. VolitionRx posted Q3 revenue that was up 32% year over year and a $5.4M net loss, while securing two notable human diagnostics agreements with Werfen and Hologic (HOLX), the analyst tells investors in a research note. With roughly 10 major diagnostics and liquid-biopsy companies engaged at various stages of partnership discussions, management expects additional licensing deals, underscoring the broad potential of the Nu.Q platform across cancer, sepsis, and epigenetic drug development, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VNRX

Unlock Now

Valuation Metrics

The current forward P/E ratio for VolitionRX Ltd (VNRX.A) is -1.66, compared to its 5-year average forward P/E of -4.05. For a more detailed relative valuation and DCF analysis to assess VolitionRX Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.05

Current PE

-1.66

Overvalued PE

-2.19

Undervalued PE

-5.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.70

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.40

Undervalued EV/EBITDA

-3.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

96.57

Current PS

9.25

Overvalued PS

350.35

Undervalued PS

-157.22

Financials

AI Analysis

Annual

Quarterly

Whales Holding VNRX

Trading Trends

People Also Watch

Frequently Asked Questions

What is VolitionRX Ltd (VNRX) stock price today?

The current price of VNRX is 0.2027 USD — it has decreased -4.69

What is VolitionRX Ltd (VNRX)'s business?

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

What is the price predicton of VNRX Stock?

Wall Street analysts forecast VNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNRX is2.25 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is VolitionRX Ltd (VNRX)'s revenue for the last quarter?

VolitionRX Ltd revenue for the last quarter amounts to 627.28K USD, increased 32.19

What is VolitionRX Ltd (VNRX)'s earnings per share (EPS) for the last quarter?

VolitionRX Ltd. EPS for the last quarter amounts to -0.05 USD, decreased -28.57

How many employees does VolitionRX Ltd (VNRX). have?

VolitionRX Ltd (VNRX) has 85 emplpoyees as of March 03 2026.

What is VolitionRX Ltd (VNRX) market cap?

Today VNRX has the market capitalization of 27.48M USD.